$Cullinan Therapeutics (CGEM.US)$
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
Cullinan Therapeutics (Nasdaq: CGEM) announced FDA clearance of its Investigational New Drug (IND) Application for CLN-978, allowing its global Phase 1 clinical trial to proceed in the U.S. for patients with moderate to severe systemic lupus erythematosus (SLE). CLN-9...

$Cullinan Therapeutics (CGEM.US)$
NEWS
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Gainers:
• $Cullinan Therapeutics (CGEM.US)$ +22.4% (Cullinan Management and Taiho Pharmaceutical to collaborate to jointly develop and commercialize CLN081/TAS6417 and Taiho's acquisition of Cullinan Pearl)
• $Lordstown Motors (RIDE.US)$ +17.2% (closes asset purchase agreement with Foxconn)
• $Applovin (APP.US)$ +15.5%(In reaction to earnings)
• $SmartRent (SMRT.US)$ +15.4%(In reaction to earnings)
• $Coupang (CPNG.US)$ +14.3%(In reaction to earn...

$Cullinan Therapeutics (CGEM.US)$ ISO this week in Biotech Pharma.